AR110755A1 - Anticuerpos dirigidos a hueso - Google Patents
Anticuerpos dirigidos a huesoInfo
- Publication number
- AR110755A1 AR110755A1 ARP180100119A ARP180100119A AR110755A1 AR 110755 A1 AR110755 A1 AR 110755A1 AR P180100119 A ARP180100119 A AR P180100119A AR P180100119 A ARP180100119 A AR P180100119A AR 110755 A1 AR110755 A1 AR 110755A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- binding fragment
- antigen
- heavy chain
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448763P | 2017-01-20 | 2017-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110755A1 true AR110755A1 (es) | 2019-05-02 |
Family
ID=61581744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100119A AR110755A1 (es) | 2017-01-20 | 2018-01-18 | Anticuerpos dirigidos a hueso |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10844115B2 (https=) |
| EP (1) | EP3571226A2 (https=) |
| JP (3) | JP7227138B2 (https=) |
| KR (3) | KR102613463B1 (https=) |
| CN (2) | CN111032690B (https=) |
| AR (1) | AR110755A1 (https=) |
| AU (1) | AU2018210270A1 (https=) |
| BR (1) | BR112019013986A2 (https=) |
| CA (1) | CA3050884A1 (https=) |
| IL (2) | IL268114B2 (https=) |
| MX (2) | MX2019008549A (https=) |
| MY (2) | MY194819A (https=) |
| SG (1) | SG11201906663VA (https=) |
| TW (3) | TWI832600B (https=) |
| UY (1) | UY37576A (https=) |
| WO (1) | WO2018136698A2 (https=) |
| ZA (1) | ZA201907673B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017310344A1 (en) * | 2016-08-11 | 2019-03-07 | Precithera, Inc. | TGF-β antagonist conjugates |
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TWI832600B (zh) * | 2017-01-20 | 2024-02-11 | 美商健臻公司 | 骨靶向抗體 |
| WO2019232283A1 (en) | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| KR20210030411A (ko) * | 2018-07-10 | 2021-03-17 | 사노피 | Cd38 및 tgf-베타를 표적으로 하는 암에 대한 병용 요법 |
| JP2022513079A (ja) * | 2018-11-19 | 2022-02-07 | バイオカルティス エン フェー | 統合ワークフローでの低コピー数の核酸の強化された検出 |
| CA3219219A1 (en) | 2021-05-07 | 2022-11-10 | Baylor College Of Medicine | Treatment of moderate-to-severe osteogenesis imperfecta |
| CA3226401A1 (en) * | 2021-07-20 | 2023-01-26 | William Marsh Rice University | Engineered compositions for bone-targeted therapy |
| MX2024005344A (es) | 2021-11-01 | 2024-07-19 | Genzyme Corp | Tratamiento de la osteogenesis imperfecta. |
| CN115403657A (zh) * | 2022-06-23 | 2022-11-29 | 浙江大学 | 一种TGF-β3生长因子的亲和多肽及其应用 |
| AU2024229931A1 (en) | 2023-02-27 | 2025-09-11 | The Trustees Of Columbia University In The City Of New York | Bone-directed therapeutics for the treatment of cancer |
| JP7479537B1 (ja) * | 2023-03-31 | 2024-05-08 | ナガヨシ製薬株式会社 | 咳を止め、痰を減らし、免疫力を向上させるイナゴマメ多糖類およびその調製方法と使用 |
| WO2025184427A1 (en) * | 2024-02-27 | 2025-09-04 | Osteologic Therapeutics, Inc. | Bone-targeted antibodies and methods of use thereof |
| CN120647762B (zh) * | 2025-06-16 | 2026-01-23 | 首都医科大学附属北京友谊医院 | 一种抗β1-AR-ECII抗体及其应用 |
| CN120535618B (zh) * | 2025-07-28 | 2025-09-23 | 成都大熊猫繁育研究基地 | 一种抗大熊猫cdv单克隆抗体、杂交瘤细胞株及用途 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| US5824655A (en) | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| MX336813B (es) | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
| US6455495B1 (en) | 1997-02-14 | 2002-09-24 | The Salk Institute For Biological Studies | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents |
| EP1074563A1 (en) * | 1999-08-02 | 2001-02-07 | F. Hoffmann-La Roche Ag | Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof |
| US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| JP2006523609A (ja) | 2002-12-31 | 2006-10-19 | アルタス ファーマシューティカルズ インコーポレイテッド | タンパク質結晶およびイオン性ポリマーの複合体 |
| JP2006525362A (ja) | 2003-04-30 | 2006-11-09 | ジェンザイム コーポレーション | 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用 |
| WO2005010049A2 (en) | 2003-07-09 | 2005-02-03 | Eli Lilly And Company | Tgf-beta1 ligands |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| CA2559228C (en) | 2004-04-21 | 2016-06-21 | Enobia Pharma Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| TR201901929T4 (tr) | 2005-02-08 | 2019-03-21 | Genzyme Corp | TGFBeta'ya antikorlar. |
| TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| EP1966243B1 (en) * | 2005-12-23 | 2012-02-15 | Eli Lilly And Company | Tgf-beta binding antibodies |
| JP6071165B2 (ja) | 2007-05-31 | 2017-02-01 | ゲンマブ エー／エス | 安定なＩｇＧ４抗体 |
| US8574577B2 (en) * | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| KR101658247B1 (ko) | 2008-01-03 | 2016-09-22 | 더 스크립스 리서치 인스티튜트 | 모듈 인식 도메인을 통한 항체 표적화 |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| WO2010072691A1 (en) | 2008-12-22 | 2010-07-01 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| WO2010124276A2 (en) | 2009-04-24 | 2010-10-28 | Vanderbilt Universtiy | Anti-tgf-beta induction of bone cell function and bone growth |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| CN103732623B (zh) | 2011-06-03 | 2017-09-29 | 佐马技术有限公司 | 对TGF‑β具有特异性的抗体 |
| EP2718325A4 (en) | 2011-06-13 | 2015-03-11 | ABGENOMICS COöPERATIEF U A | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF |
| KR20140084201A (ko) | 2011-10-19 | 2014-07-04 | 알렉시온 파마 홀딩 | 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법 |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US10052366B2 (en) * | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| WO2013178736A1 (en) | 2012-05-31 | 2013-12-05 | Innate Pharma | Tlr3 binding agents |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| CA2886607A1 (en) | 2012-10-17 | 2014-04-24 | Cedars-Sinai Medical Center | Molecular signatures of ovarian cancer |
| HRP20181939T4 (hr) * | 2013-03-20 | 2022-05-13 | Genzyme Corporation | Postupci za liječenje osteogenesis imperfecta |
| RS61778B1 (sr) | 2013-05-06 | 2021-06-30 | Scholar Rock Inc | Kompozicije i postupci za modulaciju faktora rasta |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| JP2017507900A (ja) | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| US20170216401A1 (en) * | 2014-03-17 | 2017-08-03 | Piotr Jachimczak | Combination for use in a method of treating cancer |
| CN107428825A (zh) | 2014-10-10 | 2017-12-01 | 创祐生技股份有限公司 | 治疗及/或预防肿瘤生长、侵袭及/或转移的方法 |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| EP3770171A1 (en) | 2015-04-03 | 2021-01-27 | XOMA Technology Ltd. | Treatment of cancer using inhibitors of tgf-beta and pd-1 |
| KR20250004095A (ko) | 2015-04-17 | 2025-01-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| WO2017011773A2 (en) * | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Codon-optimized nucleic acids encoding antibodies |
| US20200231652A1 (en) * | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| AU2017310344A1 (en) | 2016-08-11 | 2019-03-07 | Precithera, Inc. | TGF-β antagonist conjugates |
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TWI832600B (zh) | 2017-01-20 | 2024-02-11 | 美商健臻公司 | 骨靶向抗體 |
-
2018
- 2018-01-18 TW TW111146907A patent/TWI832600B/zh active
- 2018-01-18 AR ARP180100119A patent/AR110755A1/es unknown
- 2018-01-18 TW TW107101790A patent/TWI788321B/zh active
- 2018-01-18 TW TW113101673A patent/TW202421659A/zh unknown
- 2018-01-19 CN CN201880007783.2A patent/CN111032690B/zh active Active
- 2018-01-19 CA CA3050884A patent/CA3050884A1/en active Pending
- 2018-01-19 MX MX2019008549A patent/MX2019008549A/es unknown
- 2018-01-19 US US15/875,125 patent/US10844115B2/en active Active
- 2018-01-19 KR KR1020197024021A patent/KR102613463B1/ko active Active
- 2018-01-19 MY MYPI2019006821A patent/MY194819A/en unknown
- 2018-01-19 IL IL268114A patent/IL268114B2/en unknown
- 2018-01-19 CN CN202410319667.1A patent/CN118121696A/zh active Pending
- 2018-01-19 BR BR112019013986-9A patent/BR112019013986A2/pt not_active IP Right Cessation
- 2018-01-19 EP EP18709437.0A patent/EP3571226A2/en active Pending
- 2018-01-19 IL IL317592A patent/IL317592A/en unknown
- 2018-01-19 KR KR1020237042558A patent/KR102755284B1/ko active Active
- 2018-01-19 UY UY0001037576A patent/UY37576A/es not_active Application Discontinuation
- 2018-01-19 JP JP2019539277A patent/JP7227138B2/ja active Active
- 2018-01-19 WO PCT/US2018/014350 patent/WO2018136698A2/en not_active Ceased
- 2018-01-19 AU AU2018210270A patent/AU2018210270A1/en not_active Abandoned
- 2018-01-19 MY MYPI2022003998A patent/MY207919A/en unknown
- 2018-01-19 KR KR1020257000987A patent/KR20250012197A/ko active Pending
- 2018-01-19 SG SG11201906663VA patent/SG11201906663VA/en unknown
-
2019
- 2019-07-17 MX MX2022008073A patent/MX2022008073A/es unknown
- 2019-11-20 ZA ZA2019/07673A patent/ZA201907673B/en unknown
-
2020
- 2020-10-23 US US17/079,285 patent/US12098194B2/en active Active
-
2023
- 2023-02-08 JP JP2023017271A patent/JP7597836B2/ja active Active
-
2024
- 2024-08-13 US US18/802,674 patent/US20250074975A1/en active Pending
- 2024-11-27 JP JP2024205967A patent/JP2025028981A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| AR105026A1 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| AR112257A1 (es) | Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| AR101875A1 (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| JP2018536393A5 (https=) | ||
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| MX2018013176A (es) | Anticuerpos anti-basigin humanizados y el uso de los mismos. | |
| AR103839A1 (es) | DÍMEROS scFv-Fc QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 CON AFINIDAD, AVIDEZ Y ESPECIFICIDAD ELEVADAS | |
| JP2021517459A5 (https=) | ||
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| PE20230384A1 (es) | Anticuerpos cd163 o proteinas de union | |
| PE20230682A1 (es) | Anticuerpo anti-ox40 y usos del mismo | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
| PE20240589A1 (es) | ANTICUERPOS CD1a Y SU USO | |
| RU2017122172A (ru) | Антитела к IL-17C | |
| AR116937A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
| AR122286A1 (es) | Anticuerpos potenciadores del factor h y usos de estos | |
| MX2021014885A (es) | Composiciones de anticuerpos anti-tnf, y métodos para el tratamiento de la artritis psoriásica. | |
| AR131528A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR132159A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR132043A1 (es) | Anticuerpos muc1 y métodos de uso | |
| PE20231854A1 (es) | Anticuerpo monoclonal o fragmento de union al antigeno del mismo que se une especificamente al gd2 (gangliosido gd2), y uso del mismo |